RM

Robert Mittendorff

General Partner at B Capital

San Francisco Bay Area

Overview 

Robert Mittendorff is the General Partner and Head of Healthcare at B Capital Group, overseeing investments in various sectors including medical devices, robotics, health IT, and AI. With a strong background in venture capital and a track record of successful investments in companies like Carlsmed and Nalu Medical, Mittendorff brings expertise in strategic partnerships and corporate development to drive business growth in the healthcare industry.

Work Experience 

  • General Partner and Head of Healthcare

    2021 - Current

B Capital Group is a venture capital firm that backs global entrepreneurs in the field of information technology.

  • Board Member

    2024

Nalu Medical is a medical technology company that develops innovative solutions for patients with chronic neuropathic pain.

Raised $200,915,367.00 from Pura Vida Investments, Aperture Venture Partners, Advent Life Sciences, Longitude Capital, B Capital, Decheng Capital, Endeavour Vision, Novo Holdings, Gilde Healthcare and MVM Life Science Partners.

  • Member Board Of Directors

    2022

Capital Rx is a healthtech platform that provides pharmacy benefit management solutions.

Raised $252,960,628.00 from Prime Therapeutics.

  • Member Board Of Directors

    2022

The company manufactures and sells the aprevo™ digital-to-device 3-D printed implant system for lumbar spine surgery.

Raised $96,985,000.00 from U.S. Venture Partners and B Capital.

  • Member Board Of Directors

    2021

Lively is a modern Health Savings Account (HSA) platform for employers and individuals.

Raised $122,200,000.00 from B Capital, Costanoa Ventures and Titanium Ventures.

  • Member Board of Directors

    2021

HotSpot Therapeutics is a developer of a therapy platform designed to discover medicines and provide proper treatment.

Raised $210,000,000.00 from Pavilion Capital, Revelation Partners, SR One, LSP BioVentures, Monashee Investment Management, B Capital, Atlas Venture, Sofinnova Partners, CaaS Capital Management and Pivotal bioVenture Partners.

  • Board Member

    2022

Triumvira Immunologics is an immunotherapy company that develops novel T cell therapies for cancer.

Raised $100,000,000.00 from Myeloma Investment Fund, Multiple Myeloma Research Foundation, Northpond Ventures, Leaps by Bayer, B Capital, ATEM Capital Fund LP, Northpond Ventures, Bloom Burton & Co., Centre for Commercialization of Cancer Immunotherapy and Leaps by Bayer.

  • Board Observer

    2024

Volastra Therapeutics is a biotechnology company developing novel therapies for the treatment of metastatic cancers.

Raised $119,000,000.00 from Polaris Partners, Cornell University, Droia Ventures, Eli Lilly, Catalio Capital Management, ARCH Venture Partners, Vida Ventures and Meyer Ventures.

  • Board Observer

    2021

Aetion provides real-world evidence (RWE) and outcomes-based analytics solutions to life science companies and payers.

Raised $203,600,000.00 from B Capital, Warburg Pincus, Foresite Capital, Flare Capital Partners and New Enterprise Associates.

Articles About Robert

Relevant Websites